If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GLP-1 / glucagon dual receptor agonist (BI 456906)
Batch documentation
Survodutide is an investigational GLP-1/glucagon dual agonist. For research sourcing, review identity, same-lot documentation, storage, and destination-market requirements.
Overview
Survodutide, carrying the development code BI 456906, is an investigational dual co-agonist hitting the GLP-1 and glucagon receptors. The clinical-development program runs through a Boehringer Ingelheim / Zealand Pharma partnership and is in Phase 3 for both chronic weight management and metabolic-liver indications, MASH (metabolic-associated steatohepatitis) chief among them. Receptor coverage maps to GLP-1R plus GCGR with no GIP arm, mirroring Mazdutide and contrasting with the GIP-containing dual / tri-agonist class. That positioning makes the molecule useful in two distinct ways: as a research tool for studying glucagon-pathway pharmacology isolated from GIP signalling, and as a clinical asset for indications where glucagon-mediated hepatic energy expenditure delivers therapeutic value. For research-lab buyers, Vialdyne releases Survodutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The catalogue 10 mg fill covers bench-scale aliquot work in the typical research context. The release packet leans particularly hard on ESI-MS identity confirmation, the structural proximity to other GLP-1 / glucagon dual co-agonists means catalogue-level cross-supplier confusion is an operationally real failure mode, and LC-MS/MS sequence verification can be included when required by the buyer’s written analytical scope.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: academic and contract research laboratories.
Specifications
Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COASurvodutide 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
An investigational compound advancing through Phase 3 development at Boehringer Ingelheim / Zealand Pharma, this has not been approved as a finished drug. Supply is for research use only. Although a CAS is commonly cited, verify it per batch COA.
Selected literature
Frequently asked questions
Keep the sealed lyophilised vial frozen at -20 C, protected from moisture, until the working session, with the re-test date carried on the released-batch certificate. As a lipidated dual co-agonist it should not be reconstituted until point of use; once in solution, split into single-use aliquots at once and treat freeze-thaw cycle count as the dominant driver of measured-potency loss, holding cumulative thaws to three or fewer per aliquot. Log any storage-temperature excursion in the receiving record, since that is the trigger for an out-of-schedule potency check before the lot is cleared for use.
Because it and its nearest sibling occupy the identical GLP-1R plus GCGR receptor space yet differ in sequence and lipidation chemistry, receptor-coverage description alone cannot distinguish the two at receiving inspection. Anchor identity on ESI-MS at the expected lipidated-peptide mass together with RP-HPLC main-peak integration, and add sequence confirmation by peptide-mapping to verify the specific backbone. Match those results, and where reported the counter-ion and water-content figures, to the released-lot certificate before benchmarking any model against a clinical data reference. That per-batch verification, not the development-partner label, is what protects against an inadvertent swap.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides